Subscribe
e.g. organoids

SciSparc Receives Approval to Conduct Its Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome

SciSparc Ltd. announced the approval of the Israeli Ministry of Health to conduct its clinical trial titled “A randomized, double-blind, placebo controlled, cross-over study to evaluate the efficacy, safety and tolerability of daily oral SCI-110 in treating adults with Tourette Syndrome”.
[SciSparc, Ltd.]
Press Release
Published In
NewslettersNeural Cell News
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News

89bio’s Phase IIb ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and...

[89bio, Inc.] 89bio, Inc. announced positive topline data from the Phase IIb ENLIVEN trial evaluating treatment with pegozafermin in patients with NASH. In the study, both the 44mg Q2W and 30mg QW doses met, with high statistical significance.
Hepatic Cell NewsNewsletters
Read more

LncRNA-MIAT Activates Hepatic Stellate Cells via Regulating Hippo Pathway and Epithelial-to-Mesenchymal Transition

[Communications Biology] The expression of myocardial infarction-associated transcript (MIAT) was up-regulated during liver fibrosis. Silencing MIAT led to the suppression of hepatic stellate cell proliferation and collagen expression.
Hepatic Cell NewsNewsletters
Read more

Targeting WDxR Motif Reprograms Immune Microenvironment and Inhibits Hepatocellular Carcinoma Progression

[EMBO Molecular Medicine] WD-repeat 6 (WDR6) deficiency in hepa1-6 cells drastically inhibited the growth and lung metastasis of orthotopically implanted tumors in immune-competent C57BL/6J mice.
Hepatic Cell NewsNewsletters
Read more
Brought to you by